Memantine Hydrochloride Solution
Product Images NDC 62135-943

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 62135-943). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Memantine Hydro Bot Label)

FDA Label Image

Image Description (Memantine Hydro Fig 1)

Image Description (Memantine Hydro Fig 1)
The text describes a graph or chart showing the mean change from the baseline in ADCS-ADL score for placebo and memantine over a period of 28 weeks. The graph also shows the clinical improvement and decline of the participants. The SEM value is also included in the mean change.*
FDA Label Image

Image Description (Memantine Hydro Fig 2)

FDA Label Image

Image Description (Memantine Hydro Fig 3)

FDA Label Image

Image Description (Memantine Hydro Fig 4)

FDA Label Image

Image Description (Memantine Hydro Fig 5)

FDA Label Image

Image Description (Memantine Hydro Fig 6)

Image Description (Memantine Hydro Fig 6)
The text describes a graph showing the cumulative percentage of patients with Alzheimer's Disease by the change in ADCS-ADL score from baseline. The graph compares the results of patients who received either a placebo and donepezil or memantine and donepezil.*
FDA Label Image

Image Description (Memantine Hydro Fig 7)

FDA Label Image

Image Description (Memantine Hydro Fig 8)

Image Description (Memantine Hydro Fig 8)
The text represents a graph showing the cumulative percentage of patients who experienced a certain change from baseline in a medical trial. The x-axis shows the change score, while the y-axis shows the percentage of patients. The graph compares placebo/donepezil treatment versus memantine/donepezil treatment. The graph demonstrates that the memantine/donepezil treatment had a higher percentage of patients experiencing a positive change score, compared to the placebo/donepezil treatment.*
FDA Label Image

Image Description (Memantine Hydro Pi Fig 1)

FDA Label Image

Image Description (Memantine Hydro Pi Fig 2)

FDA Label Image

Image Description (Memantine Hydro Pi Fig 3)

FDA Label Image

Image Description (Memantine Hydro Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.